This just about sums up what's wrong with Phylogica. First of all, they're comparing Generation 1 with Generation 2 CPPs to deliver beta-lactamase into cells. They then tell us that they've got some results with Gen 1 and CRISPR/Cas9, but they don't show us any data. They proclaim that these results will translate into Generation 2 working well with CRISPR/Cas9 - with no evidence - and then they throw in the term "commercialisation" in a sad attempt to excite us.
The fact that other groups have already done this, and published, doesn't help. We have been told that Phylogica is going to use its CPPs to deliver an oligonucleotide against a disease target - that is a worthy aim and something they should focus on laser-like. Perhaps over the Christmas holiday, the scientists and management can take time to reflect on whether they want to be a therapeutic company or a "bag of tricks" outfit. You can't be both.
PYC Price at posting:
3.0¢ Sentiment: Sell Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)